MDRNA (MRNA) Reports on DiLA2's Delivery of UsiRNA to Tumors in Vivo
MDRNA, Inc. (NASDAQ: MRNA) today presented new in vivo data demonstrating continued progress in the advancement of the Company's oncology program.
J. Michael French, President and CEO, reported that MDRNA's UsiRNAs, delivered by the Company's DiLA2 platform, down-regulated a previously "non-druggable" target with subsequent reductions in tumor growth in models of liver and bladder cancer via both systemic and local delivery.
Mr. French said that MDRNA has demonstrated successful delivery of a UsiRNA targeting survivin, a protein involved in mitotic progression and inhibition of apoptosis, via intravenous administration using its DiLA2 liposome formulation in two liver cancer models.
The DiLA2 Delivery Platform is MDRNA's proprietary platform for creating novel liposomal delivery systems based on di-alkylated amino acids (DiLA2).
J. Michael French, President and CEO, reported that MDRNA's UsiRNAs, delivered by the Company's DiLA2 platform, down-regulated a previously "non-druggable" target with subsequent reductions in tumor growth in models of liver and bladder cancer via both systemic and local delivery.
Mr. French said that MDRNA has demonstrated successful delivery of a UsiRNA targeting survivin, a protein involved in mitotic progression and inhibition of apoptosis, via intravenous administration using its DiLA2 liposome formulation in two liver cancer models.
The DiLA2 Delivery Platform is MDRNA's proprietary platform for creating novel liposomal delivery systems based on di-alkylated amino acids (DiLA2).
You May Also Be Interested In
- Syngenta (SYT) settles atrazine litigation; will pay $105M in deal
- Orthofix (OFIX) Divests Sports Medicine Business Unit; Applies $145 Million to Debt
- Dow Chemical (DOW) Wins $2.16B in K-Dow Arbitration
Create E-mail Alert Related Categories
Corporate NewsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
